The Impact of Probiotic on Survival and Treatment Response in Metastatic Non-small Cell Lung Cancer Patients

The aim of this study is to evaluate the effect of a probiotic supplement containing Bifidobacterium animalis lactis BL-04 on the clinical effectiveness of immunotherapy in patients diagnosed with metastatic non-small cell lung cancer who are receiving immunotherapy.

Trial Details

NCT ID
NCT06428422
Phase
NA
Sponsor
Necmettin Erbakan University
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Bifidobacterium animalis subsp. lactis Bl-04
  • Plasebo
Locations (sample)
  • Konya, Turkey (Türkiye)|37.87135,32.48464

Key Eligibility Criteria

  • Volunteering to participate in the study.
  • Histologically confirmed diagnosis of Non-Small Cell Lung Cancer (NSCLC).
  • Patients must be in an advanced stage (incurable with surgery or radiotherapy) or have metastatic disease (Stage IV).
  • Male or female patients aged \>18 years.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →